* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
Download Neurofibromatosis Type 1
Gene expression profiling wikipedia , lookup
Genetic engineering wikipedia , lookup
Gene desert wikipedia , lookup
Therapeutic gene modulation wikipedia , lookup
Genome evolution wikipedia , lookup
Gene nomenclature wikipedia , lookup
Tay–Sachs disease wikipedia , lookup
Gene expression programming wikipedia , lookup
Population genetics wikipedia , lookup
Epigenetics of diabetes Type 2 wikipedia , lookup
Nutriepigenomics wikipedia , lookup
Fetal origins hypothesis wikipedia , lookup
Site-specific recombinase technology wikipedia , lookup
Gene therapy of the human retina wikipedia , lookup
Artificial gene synthesis wikipedia , lookup
Medical genetics wikipedia , lookup
Gene therapy wikipedia , lookup
Oncogenomics wikipedia , lookup
Saethre–Chotzen syndrome wikipedia , lookup
Genome (book) wikipedia , lookup
Epigenetics of neurodegenerative diseases wikipedia , lookup
Public health genomics wikipedia , lookup
Frameshift mutation wikipedia , lookup
Point mutation wikipedia , lookup
Microevolution wikipedia , lookup
Neurofibromatosis Type 1 Joanna Spira and Emily Stamell Neurofibromatosis Type 1 is an autosomal dominantly inherited disease that affects 1 in 3,000 to 4,000 individuals. The affected genes often show variable expressivity, as is common with autosomal dominant traits, and is characterized by caféau-lait spots (brownish spots) on the skin, Lisch nodules (benign hamartomatous nodules on the iris of the eye), and cutaneous and subcutaneous neurofibromas (fleshy benign tumors that arise along the course of nerves) (Thomas 29). Other more serious symptoms are possible, albeit less common, and include plexiform neurofibromas, optic and other central nervous system gliomas, malignant peripheral nerve sheath tumors, osseous lesions, and vasculopathy (Friedman). Neurofibromatosis Type 1 usually manifests within the first year of life, but the clinical findings continue to develop over the course of one’s lifetime. Genetics, Disease Risks, and Diagnostic Criteria As stated above, Neurofibromatosis Type I is inherited in an autosomal dominant fashion; as such, an affected parent has a fifty percent chance of passing the mutant gene onto his offspring. Of the individuals affected with Neurofibromatosis Type I, fifty percent are due to a de novo mutation in the NF1 gene. Disease manifestations are extremely variable even within familial Neurofibromatosis Type 1. The majority of Neurofibromatosis Type 1 cases are due to a heterozygous mutation in the NF1 gene. In rare instances, a homozygous mutation in one of the genes associated with hereditary non-polyposis colon cancer can lead to Neurofibromatosis Type 1. Although DNA-tests are available for diagnostic purposes, they are rarely needed (Friedman). A clinical diagnosis can be made by fulfilling two of the following seven criteria: six or more caféau-laity spots, two or more neurofibromas or one plexiform neurofibroma, freckling in the axillary or inguinal region, optic glioma, two or more lisch nodules, an osseous lesion, or finally a first degree relative with defined Neurofibromatosis Type 1 disease. Molecular Biology The NF1 gene is located on chromosome 17 on the long arm at 11.2. It is a large, about 360 kilobases with 60 exons, and unusual gene in that one of its introns contains coding sequences for at least three other genes. Neurofibromatosis Type 1 disease has been associated with over 500 different mutations in the NF1 gene and no single mutation is present in more than a few percent of families. The mutations in the NF1 gene cause a variety of genetic alterations including stop codon mutations, splice site mutations, deletions, and rearrangements, just to name a few. Most of the germline mutations cause notable shortening of the gene product, neurofibromin. The normal function of neurofibromin is not entirely understood, but it has been associated with activation of ras GTPase, which in turn controls cellular proliferation. Therefore, neurofibromin acts as a tumor suppressor (Friedman). Neurofibromin is produced in nerve cells and specialized nerve cells surrounding nerves (Genetics Home Reference). It is believed that a mutation in the NF1 gene leading to truncation of the gene product is a loss-of-function mutation. As seen in previous instances with p53 and other tumor suppressor genes, the loss of a 1 gene of this nature can cause extensive cellular proliferation and ultimately tumor growth. The molecular genetic testing for mutations in the NF1 gene is a multistep protocol, which is necessary due to the high mutation rate and variability among families. The first step is an optimized protein truncation test, which can detect as high as eighty percent of pathogenic mutations. If no mutation is found using this test, Fluorescence In Situ Hybridization (FISH) analysis is performed to detect possible gene deletions. Following FISH, direct sequencing of the coding region is performed to identify missense mutations or deletions or insertions. While southern blots can be done to identify intrageneic deletions, cytogenetic analysis tests for large-scale rearrangements (Friedman). Prenatal testing can be performed for high-risk pregnancies via amniocentesis or chorionic villus sampling if the disease-causing allele within the family has previously been identified. Prognosis The disease generally presents in early childhood with multiple café-au-lait spots which grow in size as the individual ages. Later in childhood, freckles in the axillary or inguinal regions can develop in addition to lisch nodules and optic gliomas. Neurofibromas, which are benign tumors, are more common in adults with Neurofibromatosis 1. Cancerous tumors along nerves can develop in adolescence or adulthood. Individuals diagnosed with Neurofibromatosis 1 are at an increased risk of developing other forms of cancers. In addition, high blood pressure and scoliosis are sometimes associated with this disease. Mental retardation is present in less than ten percent of individuals with Neurofibromatosis 1, although about half of the children present with learning disabilities. Possible Treatment Since Neurofibromatosis Type 1 has many clinical manifestations that vary depending on the individual, treatment plans are based solely on the individual’s disease presentation. The disease is not treated as a whole, but rather individual symptoms are dealt with. The primary complaint of individuals with Neurofibromatosis Type 1, regardless of other serious complications, is the disfigurement caused by the cutaneous and subcutaneous neurofibromas (Wolkenstein et al.). Complications with the eye, central nervous system, peripheral nervous system, spine, or long bones are referred to specialists for further treatment. Plexiform neurofibromas can lead to progressive lesions that cause significant morbidity. Current treatment for plexiform neufibromas is surgery, although other treatment options are being investigated (Packer et al.). Optic gliomas can range from asymptotic to rapidly growing tumors. Additionally, little is known about the natural course of this tumor growth and therefore there is no clear treatment plan (Czycyk et al.). Brain stem and cerebellar astrocytomas have a less aggressive course in individuals with Neurofibromatosis 1 than individuals without the disease since spontaneous regressions of the growth have been reported (Leisti et al). Individuals afflicted with Neurofibromatosis 1 have no physical limitations unless any of the other clinical manifestations that accompany Neurofibromatosis 1 requires it. 2 Conclusion Neurofibromatosis Type 1 is a defined autosomal dominant disorder that manifests itself in numerous ways. As a result, it is necessary to be familiar with the diagnostic criteria as well as the variety of clinical manifestations in order to make a proper diagnosis. In addition, there is no way to predict the severity of the disease manifestations regardless of the status of first-degree relatives. Neurofibromatosis Type 1 represents a genetic disease that is primarily diagnosed based on clinical findings. Due to the variability in the genetic mutations that cause Neurofibromatosis Type 1, it is more efficient and easier to diagnose the disease based on such clinical manifestations. References Czycyk, E., S. Jozwiak, M. Roszkowski, et al. “Optic Pathway Gliomas in Children with and without Neurofibromatosis 1.” Journal of Child Neurology. 18.7 (2003) 471. Friedman, J. M. MD, PhD. “Neurofibromatosis Type 1.” GeneReviews. 5 October 2004 <http://www.genetests.org/query?dz=nf1>. Gelehrter, Thomas D., Francis S. Collins, and David Ginsburg. Principles of Medical Genetics. Baltimore: Williams and Wilkins, 1998. Leisti, E. L., J. Pyhtinen, and M. Poyhonen. “Spontaneous Decrease of Pilocytic Astrocytoma in Neurofibromatosis Type 1.” American Journal of Neuroradiology. 17.9 (1996) 1691. “Neurofibromatosis Type 1,” Genetics Home Reference. US National Library of Medicine. 17 November 2006 sh<http://ghr.nlm.nih.gov/condition=neurofibromatosistype1>. “NF1 Gene,” Genetics Home Reference. US National Library of Medicine. 17 November 2006 <http://ghr.nlm.nih.gov/gene=nf1>. Packer, R. J., and T. Rosser. “Therapy for Plexiform Neurofibromas in Children with Neurofibromatosis 1: An Overview.” Journal of Child Neurology. 17.8 (2002) 638. Wolkenstein P., I Durand-Zaleski, J. C. Moreno, et a. “Cost Evaluations of Medical Management of Neurofibromatosis 1.” British Journal of Dermatology. 142.6 (2000) 1166. 3